Thrombosis Research
Volume 118, Issue 4 , Pages 471-477, 2006

Aspirin overprescription in primary cardiovascular prevention

  • Costantina Manes

      Affiliations

    • Institute of Cardiology, “G. d'Annunzio” University-Chieti, Italy
    • Center of Excellence on Aging, “Gabriele d'Annunzio” University Foundation-Chieti, Italy
  • ,
  • Luciano Giacci

      Affiliations

    • Società Italiana di Medicina Generale, Sezione di Chieti, Chieti, Italy
  • ,
  • Adolfo Sciartilli

      Affiliations

    • Institute of Cardiology, “G. d'Annunzio” University-Chieti, Italy
  • ,
  • Alberto D'Alleva

      Affiliations

    • Institute of Cardiology, “G. d'Annunzio” University-Chieti, Italy
  • ,
  • Raffaele De Caterina

      Affiliations

    • Institute of Cardiology, “G. d'Annunzio” University-Chieti, Italy
    • Center of Excellence on Aging, “Gabriele d'Annunzio” University Foundation-Chieti, Italy
    • CNR Institute of Clinical Physiology, Pisa, Italy
    • Corresponding Author InformationCorresponding author. Institute of Cardiology, “G. d'Annunzio” University-Chieti, c/o Ospedale S. Camillo de Lellis-Via Forlanini, 50 66100 Chieti, Italy. Tel.: +39 871 41512; fax: +39 871 402817.

Received 8 June 2005; received in revised form 28 September 2005; accepted 28 September 2005.

Abstract 

Introduction

Aspirin overprescription is of some concern, especially in still-healthy individuals, and estimates of the magnitude of this problem are lacking. We evaluated the inappropriateness of aspirin prescription by primary care physicians in primary cardiovascular prevention.

Materials and methods

Out of 20,599 patients screened by 16 primary care physicians in the Abruzzi region, central Italy, 400 patients were on treatment with aspirin for primary prevention. For each such patient, the absolute cardiovascular and coronary risks were assessed according to the Italian Cardiovascular Risk Chart for Primary Prevention and the European Society of Cardiology Coronary Risk Chart, respectively. Patients with a cardiovascular and/or coronary risk <1.0 event/100 patients/year were considered as treated inappropriately (aspirin overprescription), on the basis of previous literature.

Results

Overall, as many as 12% and 18% of patients had a cardiovascular and/or coronary risk <1.0 event/100 patients/year according to the European and the Italian charts, respectively, and therefore were defined as treated inappropriately. Patients with and without inappropriate treatment were similar with respect to smoking habits, family history and body max index. However, inappropriately treated patients had significantly lower levels of blood pressure and total cholesterol, and were more likely to be female, younger and non-diabetic than patients appropriately treated.

Conclusions

A non-negligible proportion–up to 18%–of subjects in primary prevention is currently more likely to derive harm than benefit from inappropriate aspirin use. A wider use of Cardiovascular Risk Charts should guide primary care physicians in prescribing aspirin for primary prevention.

Keywords: Aspirin, Primary prevention, Inappropriate prescriptions, Cardiovascular disease

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0049-3848(05)00417-2

doi:10.1016/j.thromres.2005.09.013

Thrombosis Research
Volume 118, Issue 4 , Pages 471-477, 2006